Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
27 September 2023 - 1:30PM
Business Wire
Her Promise Access Initiative helped prevent 57
million unplanned pregnancies putting the company approximately
halfway to its goal of preventing 120 million unplanned pregnancies
by 2030
Organon (NYSE: OGN), a global healthcare company with a focus on
women’s health, has been named to Fortune’s 2023 Change the World
list for its leadership in helping women and girls around the world
take control of their reproductive health. Organon has a portfolio
of programs, collaborations, and investments designed to lift women
for generations to come through family planning education and
contraceptive access. Fortune’s annual list recognizes companies
that have had a positive social impact through activities that are
part of their core business strategy.
Nearly 50% of pregnancies worldwide are unplanned, leading to
health risks and reduced educational and employment opportunities
for mother and child – challenges that can span generations.1, 2
Largely caused by a lack of access to contraceptive information and
services, this problem is so significant that the United Nations
Population Fund (UNFPA) has deemed unintended pregnancy a global
public health crisis.2
“Organon was founded with a vision to create a better and
healthier every day for every woman. Part of that responsibility is
to address contraception education and access barriers globally,”
said Kevin Ali, CEO of Organon. “While we are incredibly proud to
be recognized for the progress we’ve made, our work is far from
done. Together with our partners, we aim to prevent 120 million
unintended pregnancies by 2030 – a critical step toward realizing
our vision of a future in which all 4 billion women and girls
worldwide are empowered to be in control of their family
planning.”
Organon is increasing access to contraceptive choice globally
through cross-sector partnerships that are fueling public health
solutions, addressing inequities, and giving women more
opportunities to pursue education and economic independence,
including:
- Establishing Her Plan is Her Power, a $30 million,
multi-year global initiative to reduce unplanned pregnancies
through global advocacy as well as investments in community-driven
solutions in the United States, in low- and middle-income
countries, and around the globe.
- Advancing the Her Promise Access Initiative, through
which Organon works alongside partners to expand contraception
availability to the 73 lowest-income countries. The initiative has
already helped to prevent 57 million unintended pregnancies to
date.
- Establishing a new model for advancing progress in women’s
health through sustainable financing, which is being used to
mobilize capital towards initiatives that might not otherwise
receive adequate support. Programs to increase access to sexual and
reproductive health education and services are currently running in
eight countries in different phases including Mexico, Colombia,
Ecuador, Peru, Panama, as well as Thailand, Kenya, and South
Africa.
- A global grants program, which helps women and girls
take control of their reproductive health. The first cohort of
grantees includes organizations in 13 countries, including the
Dominican Republic, South Korea, Germany, and Thailand.
Fortune's Change the World list is selected and ranked by the
editors of Fortune based on the magazine's own reporting and
analysis. Nominees are assessed based on the reach, nature, and
durability of the company's impact on specific societal problems,
degree of innovation, impact on the company, and how integral the
initiative is to a company's overall strategy.
For more details on Organon’s ESG strategy, goals, and
initiatives, download the full 2022 ESG Report at
https://www.organon.com/about-organon/environmental-social-governance/.
About Organon
Organon is a global healthcare company formed to focus on
improving the health of women throughout their lives. Organon
offers more than 60 medicines and products in women’s health in
addition to a growing biosimilars business and a large franchise of
established medicines across a range of therapeutic areas.
Organon’s existing products produce strong cash flows that support
investments in innovation and future growth opportunities in
women’s health and biosimilars. In addition, Organon is pursuing
opportunities to collaborate with biopharmaceutical innovators
looking to commercialize their products by leveraging its scale and
presence in fast growing international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 10,000 employees with headquarters located in Jersey
City, New Jersey.
For more information, visit http://www.organon.com and connect
with us on LinkedIn, Instagram, Twitter and Facebook.
Cautionary Note Regarding Forward-Looking Statements
Some statements and disclosures in this press release are
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements include all statements that do not
relate solely to historical or current facts and can be identified
by the use of words such as "may," “expects,” “intends,”
“anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,”
or words of similar meaning. These forward-looking statements
include statements regarding Organon’s efforts to expand access to
contraceptive choice. Such statements are based on Organon’s
current plans and expectations and are subject to a number of risks
and uncertainties that could cause Organon’s plans and
expectations, including actual results, to differ materially from
the forward-looking statements. Organon undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described
in the forward-looking statements can be found in Organon’s filings
with the Securities and Exchange Commission ("SEC"), including
Organon’s Annual Report on Form 10-K for the year ended December
31, 2022 and subsequent SEC filings, available at the SEC’s
Internet site (www.sec.gov).
_________________________ 1 Bearak, J et al., 2022.
Country-specific estimates of unintended pregnancy and abortion
incidence: A global comparative analysis of levels in 2015-2019.
BMJ Global Health. 2 Nearly Half of All Pregnancies Are
Unintended-a Global Crisis, Says New UNFPA Report. United Nations
Population Fund. Retrieved September 6, 2023, from
www.unfpa.org/press/nearly-half-all-pregnancies-are-unintended-global-crisis-says-new-unfpa-report.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926715642/en/
Media Contacts:
Karissa Peer (614) 314-8094
Kate Vossen (732) 675-8448
Investor Contacts:
Jennifer Halchak (201) 275-2711
Alex Arzeno (646) 430-2028
Organon (NYSE:OGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Organon (NYSE:OGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024